Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering. Read More
Previous research has demonstrated the promise of using carbon monoxide (CO) as an anticancer therapeutic agent, with reactive oxygen species (ROS)-activated CO prodrugs representing a new targeted cancer treatment strategy. In the current study, researchers from Georgia State University presented the discovery and preclinical evaluation of novel ROS-activated metal-free CO prodrugs. Read More
A mouse line with severe haploinsufficiency of about 92% reduction in coiled-coil and C2 domain-containing protein 1A (CC2D1A) expression was generated by breeding of Cc2d1a-knockout allele with C2d1a -/V5-HA mice to generate a compound heterozygous murine model of autism spectrum disorder (ASD). Read More
Vidac Pharma Holding plc has announced results from an in vitro study of VDA-1275 in combination with chemotherapeutic agents to treat solid tumors. VDA-1275 is a potent small molecule that reverses cancer cell hyper glycolytic metabolism (Warburg effect). Read More
Korea Research Institute of Chemical Technology has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) and mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) inhibitors reported to be useful for the treatment of Parkinson's disease, viral infection, cancer, tuberculosis and non-alcoholic steatohepatitis. Read More
Researchers from Karolinska Institutet and collaborators have reported on the characterization of novel human anti-CD44v6 antibodies aimed to be used as anticancer agents in the radiotherapy of CD44v6-expressing cancers. Read More
Pemphigus vulgaris is an autoimmune skin disease mediated by autoantibodies to desmoglein-3 (DSG3). Since the adult murine model of this disease is quite limited, researchers aimed to develop a novel active adult pemphigus vulgaris murine model. Read More
Carisma Therapeutics Inc. has received FDA clearance of its IND application for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor (CAR)-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Read More
Researchers from Centre National de la Recherche Scientifique, Inserm, Université Claude Bernard and Université Jean Monnet have synthesized peptides acting as amyloid-β (Aβ) protein aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, cerebral amyloid angiopathy, Down syndrome, Parkinson's disease, Alzheimer's disease and motor neuron disease. Read More
DE Shaw Research LLC has identified transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others. Read More
Shanghai Institute of Organic Chemistry has described oleanamide derivatives acting as Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2)/antioxidant response element (ARE) pathway activators reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetes, multiple sclerosis, renal disorders, Huntington's disease, Parkinson's disease, autoimmune disease and Alzheimer's disease, among others. Read More
Researchers from Nagoya City University presented the development of a new mouse model with cholinergic dysfunction and amyloid pathogenesis for Alzheimer's disease. Read More
Triple-negative breast cancer (TNBC) is the most aggressive breast tumor subtype and despite treatment advances, still has shorter median overall survival rates and higher recurrence and metastatic rates than other subtypes, due to resistance to chemotherapy. Read More
